AMAG up +2.94% percent Today $AMAG High is at 35.0
Post# of 110
Posted On: 11/17/2014 11:44:55 AM
AMAG up +2.94% percent Today $AMAG High is at 35.07 and the Low 33.95 with current volume of 119,137.
Recent News posted below.
Amag Pharmaceuticals AMAG other info.
http://investorshangout.com/AMAG-Pharmaceutic...MAG-53294/
AMAG Amag Pharmaceuticals Recent Headline News
Kite Pharma's Q3 Loss Narrows Y/Y, Focus on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 2 mins ago
Kite Pharma, Inc. (KITE) reported third-quarter 2014 loss of $0.24 per share well below the year-ago loss of $37 cents per share.
BIIB: 304.87 (-0.56), KITE: 39.15 (-0.19), ANIP: 55.34 (+1.39), AMAG: 34.76 (+0.76)
Puma Biotechnology Slumps: PBYI Tumbles 9.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 59 mins ago
Puma Biotechnology has been witnessing a negative trend in its current year loss estimates and its share price falling for past few weeks
ANIP: 55.34 (+1.39), AMAG: 34.76 (+0.76), AFFX: 9.28 (-0.43), PBYI: 216.91 (+0.69)
Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:13PM CST
On Nov 14, 2014, Zacks Investment Research upgraded Affymetrix Inc. (AFFX) to a Zacks Rank #1 (Strong Buy).
BIIB: 304.87 (-0.56), ANIP: 55.34 (+1.39), AMAG: 34.76 (+0.76), AFFX: 9.28 (-0.43)
AMAG Pharmaceuticals Announces Presentation at Jefferies 2014 Global Healthcare Conference in London
GlobeNewswire - Fri Nov 14, 7:00AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG), a specialty pharmaceutical company, announced today that William Heiden, AMAG's president and chief executive officer, will present at the Jefferies 2014 Global Healthcare Conference in London on Thursday, November 20, 2014 at 9:20 a.m. GMT. The session will include a company presentation followed by a question and answer session, in which the company's business and financial outlook, strategy and growth prospects will be discussed, including the acquisition of the maternal health business of Lumara Health Inc.
AMAG: 34.76 (+0.76)
AVEO Gains on Tivozanib Agreement with Ophthotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:20PM CST
AVEO Pharmaceuticals' (AVEO) shares gained around 10.9% ever since the company announced a deal with Ophthotech (OPHT).
OPHT: 40.24 (+0.19), AVEO: 0.95 (+0.01), AMAG: 34.76 (+0.76)
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:10PM CST
AstraZeneca (AZN) and Amgen (AMGN) announced encouraging results from a phase III study on brodalumab.
JNJ: 108.28 (+0.12), AZN: 71.99 (-0.86), AMGN: 158.61 (+0.93), AMAG: 34.76 (+0.76)
Intercept Pharmaceuticals Slumps: ICPT Falls 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 7:34AM CST
Intercept Pharmaceuticals has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past few days
ANIP: 55.34 (+1.39), ICPT: 157.05 (-5.53), AMAG: 34.76 (+0.76), AFFX: 9.28 (-0.43)
Alnylam Adds Hepatic Infectious Disease Drugs to Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:40PM CST
Alnylam (ALNY) expands its hepatic infectious disease pipeline with two new candidates, ALN-HDV (hepatitis delta viral) and ALN-PDL (chronic liver).
BIIB: 304.87 (-0.56), ALNY: 88.96 (-1.16), ILMN: 180.07 (-0.43), AMAG: 34.76 (+0.76)
AMAG Pharmaceuticals Completes Acquisition of Lumara Health's Maternal Health Business
GlobeNewswire - Wed Nov 12, 3:03PM CST
-- AMAG Closes $340 Million Term Loan
AMAG: 34.76 (+0.76)
Achillion Jumps on Encouraging Data on its HCV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 4:10PM CST
Shares of Achillion Pharmaceuticals (ACHN) soared over 27% after the company reported encouraging interim results on ACH-3102.
JNJ: 108.28 (+0.12), GILD: 100.60 (-1.46), ACHN: 13.46 (-0.51), AMAG: 34.76 (+0.76)
AMAG Pharmaceuticals Has Returned 67.4% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Tue Nov 11, 10:58AM CST
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on August 11th, 2014 at $20.91. In approximately 3 months, AMAG Pharmaceuticals has returned 67.38% as of today's recent price of $34.99.
AMAG: 34.76 (+0.76)
Orexigen Turns Around with Q3 Earnings Beat, Shares Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 10:20AM CST
Orexigen (OREX) swung to profit in the third quarter of 2014 with earnings of 9 cents per share beating the Zacks Consensus Estimate of 5 cents.
OREX: 5.52 (-0.13), VVUS: 3.11 (-0.14), AMAG: 34.76 (+0.76)
Orexigen (OREX) Worth Watching: Stock Soars 33.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:25AM CST
Orexigen (OREX) was a big mover last session, with shares surging over 33% on the day.
BIIB: 304.87 (-0.56), OREX: 5.52 (-0.13), AMAG: 34.76 (+0.76), AFFX: 9.28 (-0.43)
PDL BioPharma's Q3 Earnings and Revenues Increase Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:20AM CST
PDL BioPharma (PDLI) reported third-quarter 2014 earnings of 61 cents per share, well above the year-ago earnings of 36 cents per share.
AMAG: 34.76 (+0.76), SNY: 47.29 (+0.61), PDLI: 7.88 (+0.09)
Osiris Therapeutics Beats on Q3 Earnings & Revenues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 11, 8:00AM CST
Osiris Therapeutics (OSIR) performed well above expectations with revenues increasing significantly.
CYTK: 4.20 (-0.03), BIIB: 304.87 (-0.56), OSIR: 13.23 (+0.18), AMAG: 34.76 (+0.76)
Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:20PM CST
Shares of Repros Therapeutics (RPRX) shot up 56.9% following a successful meeting with the FDA regarding Androxal.
BIIB: 304.87 (-0.56), RPRX: 9.23 (-0.11), ABBV: 65.01 (+1.01), AMAG: 34.76 (+0.76)
Theravance Biopharma Q3 Loss Widens Y/Y, Revenues Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:20AM CST
Theravance Biopharma reported a third-quarter 2014 loss of $1.72 per share.
AMAG: 34.76 (+0.76), TBPH: 17.87 (+0.39), GSK: 45.82 (+0.08), THRX: 13.18 (-0.05)
BIND Therapeutics (BIND) Worth a Look: Stock Rises 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:30AM CST
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 5% on the day.
AGEN: 2.95 (-0.03), AMAG: 34.76 (+0.76), BIND: 10.20 (-0.06), AFFX: 9.28 (-0.43)
Keryx (KERX) in Focus: Stock Adds 11.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:46AM CST
Keryx (KERX) was a big mover last session, with shares rising nearly 12% on the day.
AGEN: 2.95 (-0.03), BIIB: 304.87 (-0.56), AMAG: 34.76 (+0.76), KERX: 15.18 (-0.03)
Recent News posted below.
Amag Pharmaceuticals AMAG other info.
http://investorshangout.com/AMAG-Pharmaceutic...MAG-53294/
AMAG Amag Pharmaceuticals Recent Headline News
Kite Pharma's Q3 Loss Narrows Y/Y, Focus on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 2 mins ago
Kite Pharma, Inc. (KITE) reported third-quarter 2014 loss of $0.24 per share well below the year-ago loss of $37 cents per share.
BIIB: 304.87 (-0.56), KITE: 39.15 (-0.19), ANIP: 55.34 (+1.39), AMAG: 34.76 (+0.76)
Puma Biotechnology Slumps: PBYI Tumbles 9.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 59 mins ago
Puma Biotechnology has been witnessing a negative trend in its current year loss estimates and its share price falling for past few weeks
ANIP: 55.34 (+1.39), AMAG: 34.76 (+0.76), AFFX: 9.28 (-0.43), PBYI: 216.91 (+0.69)
Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:13PM CST
On Nov 14, 2014, Zacks Investment Research upgraded Affymetrix Inc. (AFFX) to a Zacks Rank #1 (Strong Buy).
BIIB: 304.87 (-0.56), ANIP: 55.34 (+1.39), AMAG: 34.76 (+0.76), AFFX: 9.28 (-0.43)
AMAG Pharmaceuticals Announces Presentation at Jefferies 2014 Global Healthcare Conference in London
GlobeNewswire - Fri Nov 14, 7:00AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG), a specialty pharmaceutical company, announced today that William Heiden, AMAG's president and chief executive officer, will present at the Jefferies 2014 Global Healthcare Conference in London on Thursday, November 20, 2014 at 9:20 a.m. GMT. The session will include a company presentation followed by a question and answer session, in which the company's business and financial outlook, strategy and growth prospects will be discussed, including the acquisition of the maternal health business of Lumara Health Inc.
AMAG: 34.76 (+0.76)
AVEO Gains on Tivozanib Agreement with Ophthotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:20PM CST
AVEO Pharmaceuticals' (AVEO) shares gained around 10.9% ever since the company announced a deal with Ophthotech (OPHT).
OPHT: 40.24 (+0.19), AVEO: 0.95 (+0.01), AMAG: 34.76 (+0.76)
AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:10PM CST
AstraZeneca (AZN) and Amgen (AMGN) announced encouraging results from a phase III study on brodalumab.
JNJ: 108.28 (+0.12), AZN: 71.99 (-0.86), AMGN: 158.61 (+0.93), AMAG: 34.76 (+0.76)
Intercept Pharmaceuticals Slumps: ICPT Falls 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 7:34AM CST
Intercept Pharmaceuticals has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past few days
ANIP: 55.34 (+1.39), ICPT: 157.05 (-5.53), AMAG: 34.76 (+0.76), AFFX: 9.28 (-0.43)
Alnylam Adds Hepatic Infectious Disease Drugs to Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:40PM CST
Alnylam (ALNY) expands its hepatic infectious disease pipeline with two new candidates, ALN-HDV (hepatitis delta viral) and ALN-PDL (chronic liver).
BIIB: 304.87 (-0.56), ALNY: 88.96 (-1.16), ILMN: 180.07 (-0.43), AMAG: 34.76 (+0.76)
AMAG Pharmaceuticals Completes Acquisition of Lumara Health's Maternal Health Business
GlobeNewswire - Wed Nov 12, 3:03PM CST
-- AMAG Closes $340 Million Term Loan
AMAG: 34.76 (+0.76)
Achillion Jumps on Encouraging Data on its HCV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 4:10PM CST
Shares of Achillion Pharmaceuticals (ACHN) soared over 27% after the company reported encouraging interim results on ACH-3102.
JNJ: 108.28 (+0.12), GILD: 100.60 (-1.46), ACHN: 13.46 (-0.51), AMAG: 34.76 (+0.76)
AMAG Pharmaceuticals Has Returned 67.4% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Tue Nov 11, 10:58AM CST
SmarTrend identified an Uptrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on August 11th, 2014 at $20.91. In approximately 3 months, AMAG Pharmaceuticals has returned 67.38% as of today's recent price of $34.99.
AMAG: 34.76 (+0.76)
Orexigen Turns Around with Q3 Earnings Beat, Shares Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 10:20AM CST
Orexigen (OREX) swung to profit in the third quarter of 2014 with earnings of 9 cents per share beating the Zacks Consensus Estimate of 5 cents.
OREX: 5.52 (-0.13), VVUS: 3.11 (-0.14), AMAG: 34.76 (+0.76)
Orexigen (OREX) Worth Watching: Stock Soars 33.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:25AM CST
Orexigen (OREX) was a big mover last session, with shares surging over 33% on the day.
BIIB: 304.87 (-0.56), OREX: 5.52 (-0.13), AMAG: 34.76 (+0.76), AFFX: 9.28 (-0.43)
PDL BioPharma's Q3 Earnings and Revenues Increase Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:20AM CST
PDL BioPharma (PDLI) reported third-quarter 2014 earnings of 61 cents per share, well above the year-ago earnings of 36 cents per share.
AMAG: 34.76 (+0.76), SNY: 47.29 (+0.61), PDLI: 7.88 (+0.09)
Osiris Therapeutics Beats on Q3 Earnings & Revenues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 11, 8:00AM CST
Osiris Therapeutics (OSIR) performed well above expectations with revenues increasing significantly.
CYTK: 4.20 (-0.03), BIIB: 304.87 (-0.56), OSIR: 13.23 (+0.18), AMAG: 34.76 (+0.76)
Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:20PM CST
Shares of Repros Therapeutics (RPRX) shot up 56.9% following a successful meeting with the FDA regarding Androxal.
BIIB: 304.87 (-0.56), RPRX: 9.23 (-0.11), ABBV: 65.01 (+1.01), AMAG: 34.76 (+0.76)
Theravance Biopharma Q3 Loss Widens Y/Y, Revenues Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:20AM CST
Theravance Biopharma reported a third-quarter 2014 loss of $1.72 per share.
AMAG: 34.76 (+0.76), TBPH: 17.87 (+0.39), GSK: 45.82 (+0.08), THRX: 13.18 (-0.05)
BIND Therapeutics (BIND) Worth a Look: Stock Rises 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:30AM CST
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 5% on the day.
AGEN: 2.95 (-0.03), AMAG: 34.76 (+0.76), BIND: 10.20 (-0.06), AFFX: 9.28 (-0.43)
Keryx (KERX) in Focus: Stock Adds 11.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:46AM CST
Keryx (KERX) was a big mover last session, with shares rising nearly 12% on the day.
AGEN: 2.95 (-0.03), BIIB: 304.87 (-0.56), AMAG: 34.76 (+0.76), KERX: 15.18 (-0.03)
(0)
(0)Apollo Global Management Inc. (APO) Stock Research Links
Scroll down for more posts ▼